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ABSTRACT 
Stem cell-supported high-dose chemotherapy (HDCT) is currently being evaluated in patients with high-risk pri- 
mary breast cancer (HRPBC), as defined by extensive axillary lymph node involvement. Conclusive results from ran- 
domized studies with sufficient patient numbers and follow-up are pending. We retrospectively analyzed 144 HRPBC 
patients enrolled in a single-arm trial of tandem HDCT at the University of Heidelberg to evaluate the prognostic 
value of nodal ratio, HER2/neu status, and cytokeratin-positive bone marrow cells and to compare the outcomes of 
these patients with those of a conventionally treated control group of 91 patients matched by nodal ratio, tumor size, 
combined hormone-receptor status, and HER2/neu status. The tandem HDCT regimen consisted of 2 cycles of 
induction chemotherapy followed by 2 cycles of blood stem cell-supported high-dose ifosfamide, 12 g/m2; carbo- 
platin, 900 rag/m2; and epirubicin, 180 mg/m 2. Conventionally treated patients received aregimen containing anthra- 
cycline without axanes (52 patients) or CMF (cyclophosphamide, methotrexate, and 5-flurouracil; 39 patients). With 
a median follow-up of 3.8 years, disease-free, distant disease-free, and overall survival rates were 62%, 65%, and 
84%, respectively. In univariate analysis, besides the hormone receptor status (P = .007), HER2/neu overexpression 
was the strongest predictor of earlier death (P = .017). In multivariate analysis, a nodal ratio of >_0.8 was found to be 
the only independent predictor of relapse (relative risk [RR] = 2.09; 95% confidence interval [CI], 1.21-3.60; P = .008) 
and only the absence of hormone receptors was associated with earlier death (RR = 3.59; 95% CI, 1.45-8.86; P = .006). 
Despite a trend toward later distant relapse after HDCT compared with standard-dose chemotherapy with a median 
follow-up of 3 years (P = .059), thus far, matched-pair analysis has not demonstrated significantly better survival rates 
after HDCT in all matched patients (P = .786) or in the subgroups of anthracycline-treated patients and patients with 
and without overexpression f HER2/neu. So far, the follow-up time has been too short to draw definite conclusions; 
however, patients with a nodal ratio of >_0.8, receptor-negative tumors, or HER2/neu overexpression are t high risk 
for relapse and death, irrespective of the kind of adjuvant chemotherapy. 
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INTRODUCTION 
Despite adjuvant chemotherapy, patients with high-risk 
primary breast cancer (HRPBC) often suffer relapse and 
ultimately die of the disease [1]. Preclinical experiments, ret- 
Dedicated to DI: Ha~zs Schmid. 
rospective analysis of clinical trials, and some prospective ran- 
domized trials have suggested a dose-response r lationship for 
cytotoxic treatment [2-4]. Preliminary results with myeloabla- 
tive high-dose chemotherapy (HDCT) and stem cell trans- 
plantation were encouraging [5,6], and a comparison with 
historical control groups fueled the enthusiasm for using high- 
dose adjuvant chemotherapy asa treatment option. However, 
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Table I .  Characteristics of PatieT~ts "I)'eated Acco'J.di,~g tothe 'l)mderiz 
HDCT Protocol* 
% 
Total no. of patients 144 
Median patient age (range), y 45 (22-59) 
Age at diagnosis, y 
<35 24 17 
35-45 51 35 
>45 69 48 
Stage of HRPBC 
I IA 25 17 
1113 52 36 
I l iA 49 34 
IIIB 18 13 
Menopausal status 
Premenopausal I I 0 76 
Postmenopausal 34 24 
No. of tumor-involved ALN 
Median no. (range) 14 (3-40) 
No. of patients with 
<10 22 15 
10-19 82 57 
>19 40 28 
Nodal ratio (number of tumor-involved 
ALN/number  of sampled ALN)  
Median (range) 0.66 (0. I I - I) 
No. of patients with 
<0.8 92 64 
>_0.8 52 36 
Tumor  size 
Median (range), cm 2.6 (0.6-10) 
No. of patients with tumors sized 
pTI  33 23 
pT2 65 45 
pT3 26 18 
pT4(pT4d) 18(6) 13(4) 
pTx 2 I 
No. of patients with tumors graded 
GI I I 
G2 58 40 
G3 83 58 
Gx 2 I 
Hormone-receptor status 
ER or PR positive patients 93 65 
ER and PR negative patients 51 35 
Cytokeratin-positive cells in bone 
marrow aspirate 
No 65 45 
Yes 14 10 
NA 65 45 
HER2neu overexpression (3+) 
No 84 58 
Yes 37 26 
NA 23 16 
Surgical procedure 
BCT 50 35 
MRM ,94 65 
Adjuvant Iocoregional radiotherapy of the 
Chest wall after MRM 66 46 
Draining lymph nodes 114 79 
*Data are no. of patients unless otherwise indicated. HDCT indicates 
high-dose chemotherapy; HRPBC, high-risk primary breast cancer; 
ALN, axillary lymph nodes; ER, estrogen receptor; PR, progesterone 
receptor; NA, not available; BCT, breast-conserving therapy (including 
adjuvant radiotherapy of the breast); MRM, modified radical mastectomy. 
the results of 2 small randomized trials and the preliminary 
results of 2 larger multicenter t ials comparing standard-dose 
and high-dose adjuvant chemotherapy did not show any 
significant improvement in relapse-free survival (RFS) or 
overall survival (OS) rates [7-10]. At the 36th Annual Meeting 
of the American Society of Clinical Oncology (May 20-23, 
2000, New Orleans, LA), on behalf of the Netherlands Work- 
ing Party on Autologous Transplantation i  Solid Tumors, 
Rodenhuis et al. reported for the first time a significant 
superiority of HDCT compared with standard-dose chemo- 
therapy in rates of progression-free survival and OS in 
284 patients after a median follow-up of 3 years [I 1]. 
However, even if this positive trend continues and 
reaches tatistical significance, HDCT might save only a 
certain subgroup of HRPBC patients front relapse and, 
ultimately, death from the disease. If we do not have any 
predictive factors, we need prognostic features to better 
define this group of patients who require aggressive adju- 
vant treatment. 
In this study, we analyzed 144 high-risk stage II or III 
primary breast cancer patients, including 122 patients with 
I0 or more tumor-involved axillary lymph nodes (ALN), 
who were enrolled in a single-arm trial using a tandem 
HDCT regimen from September 1992 to December 1999. 
The treatment protocol consisted of 2 cycles of conven- 
tional induction chemotherapy followed by 2 cycles of stem 
cell-supported HDCT. We retrospectively analyzed our 
data to evaluate the prognostic value of different variables 
including nodal ratio (number of tumor-involved ALN/ 
number of sampled ALN), level of HER2/neu expression, 
and presence of cytokeratin-positive bone marrow cells in 
HRPBC patients and to compare the outcomes of these 
patients with those of patients in a conventionally treated 
control group matched by the recently defined, most rele- 
vant features: nodal ratio, tumor size, combined hormone 
receptor status, and HER2/neu status [12,13]. 
PATIENTS AND METHODS 
Pat ients  
Between September  1992 and December  1999, 
144 women with HRPBC were enrolled in an adjuvant 
single-arm chemotherapy trial to evaluate the safety and 
efficacy of a tandem HDCT regimen following 2 cycles of 
conventional induction chemotherapy. The main inclusion 
criterion was stage II or III HRPBC, defined as primary 
breast cancer with 10 or more tumor-involved ALN 
(122 patients), 3 to 9 involved ALN and premenopausal ta- 
res at onset of disease (14 patients), or negative strogen- 
receptor (ER) and progesterone-receptor (PR) status 
(8 patients). Patients had to be between age 18 and 65 years 
with a Karnofsky performance score of >90%; normal 
hematologic, ardiac, renal and hepatic function; and no rel- 
evant concomitant disease. Initial work-up comprised chest 
x-ray, abdominal ultrasound, bone scan, and computed 
tomographic imaging of the brain, thorax, and abdomen. 
Patient characteristics, including age at diagnosis, stage 
of HRPBC, menopausal status, number of tumor-involved 
ALN, nodal ratio (number of tumor-involved ALN/number 
of sampled ALN), tumor size, grading, hormone-receptor 
status, presence of cytokeratin-positive cells in bone marrow 
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Table  2. Cha'racteristi~x of Matched Patie'nts Treated With CCT or  IIDCT* 
CCT HDGT P~ 
Total no. of patients, 91 9 I 
Age at diagnosis, y .04 
Median (range) 47 (27-78) 44 (22-64) 
No. of patients aged 
<35 y 7 14 
35-45 y 35 38 
>45 y 49 39 
No. of tumor-involved ALN .00 
Median (range) 9 (3-38) 12 (3-34) 
No. of patients with 
<10 53 20 
10-19 30 54 
>19 8 17 
Nodal ratio (number of I 
tumor-involved ALN/number  
of sampled ALN)~ 
Median (range), cm 0.48 (0.08- 1.0) 0.58 (0.12- 1.0) 
No. of patients with 
<0.8 cm 71 7 I 
_>0.8 cm 8 20 
Tumor  size~ I 
Median (range), cm 3.0 (0.8-9.0) 2.6 (0.8-10.0) 
No. of patients with tumors sized 
pTI 18 18 
pT2 55 55 
pT3 13 13 
pT4 (pT4d) 5 (0) 5 ( I )  
No. of patients with tumors graded .57 
GI  2 I 
G2 39 41 
G3 50 49 
Hormone-receptor  status~ I 
ER- or PR-positive patients 59 59 
ER- and PR-negative patients 32 32 
HER2/neu overexpression (3+)~: I 
Yes 22 22 
No or NA 69 69 
(NA)  (14) (27) 
Surgical procedure .08 
BeT  40 32 
MRM 51 59 
Adjuvant Iocoregional .00 
radiotherapy, % 
Chest wall after MRM 18 40 
Draining lymph nodes 69 76 
*CCT indicates conventional chemotherapy; HDCT, high-dose 
chemotherapy; ALN, axillary lymph nodes; ER, estrogen receptor; PR, 
progesterone r ceptor; NA, not available; BCT, breast-conserving 
therapy (including adjuvant radiotherapy of the breast); MRM, modi- 
fied radical mastectomy. 
tP value of chi-square t sts. 
$This variable was used for matching. 
aspirate, HER2/neu status, surgical procedure, and adjuvant 
locoregional radiotherapy, are given in detail in Table 1. 
Level of HER2/neu expression was measured by immuno- 
histochemical staining on primary tumor sections using the 
monoclonal ntibody 3B5. 
The study was conducted according to the guidelines of 
the Joint Ethical Committee of the University of Heidelberg. 
All patients gave informed consent to participate in the study. 
By searching all available records from the cancer eg- 
istry of the University of Heidelberg Department of Gyne- 
cology and Obstetrics for patients with HRPBC who 
received conventional djuvant chemotherapy during the 
same time period, we found 91 patients who could be 
matched for nodal ratio (<0.8, >-0.8), rumor size (pT1, pT2, 
pT3, pT4), combined hormone-receptor status (ER or PR 
positive versus ER and PR negative), and expression of 
HER2/neu (3+, 0-2+, or unknown) to 91 patients treated 
according to the tandem t lDCT protocol. The matching 
criteria were chosen according to the risk factors defined by 
Nieto et al. [12,13]. Characteristics of matched patients, 
including age at diagnosis, number of tumor-involved ALN, 
nodal ratio, tumor size, grading, combined hormone-receptor 
status, HER2/neu status, surgical procedure, and adjuvant 
locoregional radiotherapy are given in Table 2. 
Cytotox ic  Therapy  
High-Dose Regimen. In 141 patients, induction chemo- 
therapy consisted of 2 cycles of ifosfamide, 2500 mg/m 2, as a 
20-hour intravenous (IV) infusion on days 1 to 3 and epiru- 
bicin, 40 mg/m 2, as a 4-hour IV infusion on days 1 to 3 and 
then repeated on day 22. Three patients received 2 cycles of 
paclitaxel, 45 mg/m, as a 1-hour IV infusion on days 1 to 3, 
ifosfamide, 2000 mg/m 2, as a 4-hour IV infusion on days 1 
to 3, and epirubicin, 30 mg/m 2, as a 1-hour IV infusion on 
days 1 to 3 and repeated on day 22 (Figure 1). R-metHuG- 
CSF (filgrastim) (Neupogen; Amgen Inc, Thousand Oaks, 
CA), 300 ~tg/d subcutaneously (SC), was administered to 
accelerate neutrophil recovery and to mobilize progenitor 
cells in the bloodstream. Peripheral blood stem cell (PBSC) 
collection began after induction chemotherapy, when 
CD34" cells were measurable in the peripheral blood. 
Leukapheresis was performed using Fenwal CS3000 (Baxter 
Deutschland GmbH, Munich, Germany) or Spectra (Cobe 
Laboratories, Lakewood, CA) equipment. Between i0 L and 
20 L were processed at flow rates of 70 to 150 mL/min. For 
PBSC collection, large-bore catheters were inserted into the 
patients' jugular veins as previously described [ 14]. 
The first stem cell-supported HDCT was administered 
approximately 4 weeks after the last cycle of induction chemo- 
therapy. The tandem HDCT consisted of 2 cycles of PBSC- 
supported high-dose ifosfamide (total dose of 12,000 rag/m2), 
epirubicin (180 rag/m2), and carboplatin (900 mg/m 2) (Fig- 
ure 1). The total doses of all drugs were delivered over a 
period of 5 days. Ifosfamide was given as a 24-hour continu- 
ous IV infusion; epirubicin was administered over 4 hours 
IV and carboplatin over 2 hours IV. Carboplatin was not 
included in the regimen for the first 5 patients. Mesna was 
given at the same dosage as ifosfamide, on days 1 to 5, fol- 
lowed by an additional administration at 50% of the ifos- 
famide dosage on day 6. The interval scheduled between the 
first and second HDCT was 4 to 6 weeks. 
PBSCs were reinfused 48 hours after the end of HDCT, 
and no cytokines were given following transplantation. The 
patients received prophylactic antimicrobial therapy with 
ciprofloxacin (1000 rag/d) and fluconazole (400 rag/d). 
To treat hormone receptor-posit ive tumors, pre- 
menopausal patients received goserelin, 3.6 mg SC, once a 
month starting from the first cycle of induction chemotherapy 
and continuing for 2 years or until relapse. Postmenopausal 
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Endocrine 
therapy 
Leukaphereses 
Ifosfamide 7.5 g/m 2 
Epirubicin 120 mg/m 2 
I Paclitaxe1135 mg/m2"~ b Ifosfamid 6 g/m 2 | Epirubicin 90 mg/m 2 .) 
G-CSF 300 !Jg 
Transplantation 
Ifosfamide 12 g/m 2 
Epirubicin 180 mg/m 2 
Carboplatin 900 mg/m 2c 
premenopausal Goserelin I~- 2 years or relapse 
postmenopausal Tamoxifen # 5 years or relapse 
Figure I. Treatment plan: tandem high-dose protocol; "number of patients; haltered induction chemotherapy in 3 patients; ~ was not 
included for the first 5 patients. G-CSF indicates granulocyte-colony-stimulating factor.
patients received tamoxifen, 20 to 30 mg/d orally (PO), start- 
ing at least 6 weeks after the last PBSC-supported high-dose 
treatment and continuing for 5 years or until relapse. 
All 50 patients who underwent breast-conserving 
surgery received locoregional radiotherapy of the breast at a 
dose of 50 Gy, with a boost of 10 Gy to the tumor bed. For 
patients undergoing modified radical mastectomy, there was 
no general recommendation for radiotherapy of the chest 
wall and draining lymph nodes at the beginning of the trial. 
From August 1996 on, locoregional irradiation was included 
in the protocol  for all patients. Consequently, 66 of 
94 patients who received a mastectomy underwent locore- 
gional radiotherapy of the chest wall. In 114 patients, we 
administered radiotherapy tothe draining lymph nodes. 
Conventional Treatment of Matched Patients. Nine 
patients received 3 to 5 cycles of CMF (cyclophosphamide, 
500 mg/m 2 IV; methotrexate, 40 mg/m 2 IV; and 5-fluoro- 
uracil, 600 mg/m 2IV) on day 1 and 8 and again on day 29. 
Thirty patients received 6 cycles of CME 
A total of 52 patients received the following anthracycline- 
containing regimens: 1 patient received 8 cycles of doxoru- 
bicin, 60 mg/m 2I~, and cyclophosphamide, 600 mg/m 2IV,, on 
day 1 and again on day 22; 6 patients received 4 to 6 cycles of 
epirubicin, 90 mg/m 2IM, and cyclophosphamide, 600 lng/m 2 
IV on day 1 and again on day 22 (E90C); 3 tpatients received 
5 to 6 cycles of 5-fluorouracil, 600 mg/m IV, epirubicin, 
60 mg/m 2IV, and cyclophosphamide, 600 mg/m 21V,, on day 1 
and again on day 22 (FEC); and 42 patients received 4 cycles 
Of E90C followed by 3 cycles of CME 
With the exception of 4 premenopausal patients who 
refused endocrine treatment, premenopausal patients with 
hormone receptor-positive minors received goserelin, 3.6 mg 
SC, once a month for 2 years or tamoxifen, 20-30 mg/d PO, 
for 5 years. With the exception of 2 postmenopausal 
patients who refused endocrine treatment, postmenopausal 
patients with hormone receptor-positive tumors received 
tamoxifen, 20-30 mg/d PO for 5 years. 
All 40 patients who underwent breast-conserving 
surgery received locoregional radiotherapy of the breast at a 
dose of 50 Gy, with a boost of 10 Gy to the tumor bed. 
Eighteen of 59 patients who had undergone mastectomy 
underwent locoregional radiotherapy of the chest wall. In 
69 patients, we administered radiotherapy to the draining 
lymph nodes. 
Immunocytochemist ry  
Bone marrow aspiration from the iliac crest was per- 
formed as a staging procedure before chemotherapy was ini- 
tiated. Tumor cells were detected using an immunostaining 
method with a cocktail of 4 monoclonat epithelial-specific 
antibodies: antibody 5D3 (BioGenex, San Ramos, CA), 
HEA 125 (Progen Biotechnik GmbH, Heidelberg, Ger- 
many) and 2 murine monoclonal antibodies, BM7 and BM8, 
with a specificity for glycosylated side-chains of breast 
mucin, (developed by S. Kaul, University of Heidelberg 
Department of Gynecology and Obstetrics, Heidelberg, 
Germany) as previously described [15]. Per specimen, 4 x 
106 cells were screened using automated cellular imaging 
system picture analysis (ACIS; ChromaVision, San Juan 
Capistrano, CA) for tumor cells. Bone marrow aspirate was 
scored positive when at least 1 tumor cell per 106 bone mar- 
row cells was detected. 
Statistical Analysis 
Disease-flee survival (DFS), distant disease-free survival 
(DDFS), and OS periods were taken as clinical outcome 
variables. DFS was measured from the date of surgery until 
the time of relapse, death, or last contact. DDFS was meas- 
ured from the date of surgery until the time of distant 
relapse, death, or last contact. Distant relapse was defined as 
BB&MT 335 
A. Sch~eeweiss et al. 
disease relapse at a site other than in the ipsilateral breast, 
chest wall, or ALN or above the ipsilateral clavicle. OS was 
calculated from the date of surgery to death or to the date of 
the last patient contact. Survival curves were estimated using 
the Kaplan-Meier product limit method [16]. Univariate 
and multivariate analyses were performed to identify risk 
factors associated with DFS, DDFS, and OS. Differences 
between the survival curves were compared using the log- 
rank test [17]. Multivariate analysis was performed using the 
Cox regression model with stepwise analysis (P value for 
entry = .15 and P value for removal = .05) [18]. The distri- 
bution of patients and tumor characteristics among the 
matched patients treated with HDCT or conventional 
chemotherapy, respectively, were compared using the chi- 
square test. All tests were performed using Systat software 
(version 7.0; Systat, Witzenhausen, Germany). 
In 144 patients treated with tandem HDCT, the follow- 
ing risk factors were examined in a univariate analysis: age at 
diagnosis (<35 years versus 35-45 years versus >45 years), 
stage (II versus III), menopausal status (premenopausal versus 
postmenopausal), number of tumor-involved ALN (<10 ver- 
sus 10-19 versus >19), nodal ratio (<0.8 versus >0.8), tumor 
size (pT1 versus pT2 versus pT3 versus pT4), grading (G1 
versus G2 versus G3), combined hormone receptor status 
(ER or PR positlve versus ER and PR negative), presence of 
cytokeratin-positive cells in bone marrow aspirate (yes versus 
no), HER2/neu status (3+ versus 0-2+), surgical procedure 
(breast-conserving surgery with adjuvant radiotherapy of the 
breast versus mastectomy), and adjuvant locoregional radio- 
therapy of the chest wall or draining lymph nodes (yes versus 
no). Variables that were significant in the univariate analysis 
were included in a multivariate analysis as stated above. 
Using the risk factors defined by Nieto et al. [12,1311 and 
confirmed by the results of our analysis, HDCT patients 
were matched to HRPBC patients from the cancer egistry 
of the University of Heidelberg Department of Gynecology 
and Obstetrics, who received conventional djuvant chemo- 
therapy during the same period. The kind of adjuvant 
chemotherapy was examined as a risk factor affecting DDFS 
and OS in all matched patients, in the subgroup of patients 
who received anthracyclines, and in the subgroups of 
patients with and without overexpression f HER2/neu. 
RESULTS 
HDCT with Autologous Blood Stem Cell 
Transplantation 
The treatment was completed as scheduled in 125 of the 
144 patients. One patient received cyclophosphamide (total 
dose of 1800 mg/m e) instead of ifosfamide during the sec- 
ond cycle of induction chemotherapy because of an ifos- 
famide-induced psychosis following the first cycle. Four 
patients received an additional third cycle of induction 
chemotherapy because of insufficient stem cell harvesting 
after the second cycle. One patient received cyclophos- 
phamide (total dose of 6000 mg/m 2) instead of ifosfamide 
during the first course of myeloablative HDCT because of 
reduced creatine clearance9 In 3 patients, the regimen of the 
second course of HDCT was changed. Two patients 
received cyclophosphamide (total dose of 6000 mg/m 2) 
instead of ifosfamide, 1patient because of neurologic distur- 
bances after the first treatment with HDCT and 1 patient 
because of reduced creatine clearance. One patient devel- 
oped elevated levels of liver enzymes after the first cycle of 
HDCT. In this patient, the second cycle of HDCT con- 
sisted of paclitaxel (total dose of 180 mg/m2), etoposide (total 
dose of 1500 lllg/n12), and thiotepa (total dose of 600 mg/m 2) 
divided over 3 days. Eleven patients were withdrawn from 
the study after the first cycle of PBSC-supported HDCT. 
The reasons for withdrawal were refusal to proceed 
(5 patients), severe hemorrhagic colitis (2 patients), severe 
neurologic disturbances (2 patients), alloreactive antibodies 
against platelets and no appropriate cross-matched donors 
available (1 patient), and retrospectively preexisting chronic 
hepatitis B (1 patient). 
The median time intervals between the last cycle of induc- 
tion chemotherapy and the first cycle of HDCT and between 
the first and second cycles of HDCT were 6 weeks (range, 
4-11 weeks) and 7 weeks (range, 4-16 weeks), respectively. 
HDCT was supported with a median number of 4.5 x 
106 CD34 + cells/kg (range, 1.9-26.1 x 106 cells/kg), which 
were mainly collected following the last cycle of induction 
chemotherapy. 
The tandem HDCT regimen was well tolerated. There 
was no difference in the hematological reconstitution and 
transfusion requirements between the first and second cycles 
of HDCT. After the first and second transplantations, a letkko- 
cyte count of 1.0 x 109/L was observed after median times of 
12 days (range, 7-16 days) and 12 days (range, 6-19 days), a 
' 9 9 9 neutrophfl count of 0.5 x 10/L after me&an rimes of 12 days 
(range, 7-16 days) and 13 days (ran gge , 6-20 days), and an 
unsupported platelet count of 20 x 10/L after median times 
of 9 days (range, 0-20 days) and 10 days (range, 0-15 days), 
respectively. Following each cycle of HDCT,  patients 
received a median number of 2 transfusions of platelets and 
2 transfusions of packed red blood cells. 
The nonhematological toxicity resulting from HDCT 
was generally moderate. Again, we observed no remarkable 
difference between the first and second cycles of HDCT. No 
treatment-related deaths were observed within 100 days of 
transplantation. The most frequent nonhematological toxicity 
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Figure 2. Disease-free survival (DFS), distant disease-free survival 
(DDFS), and overall survival (OS) rates following the initial surgery in 
144 patients who were nrolled in the high-dose chemotherapy trial. 
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Table 3. Results of the Univariate A*zalysis: Prog~zostic Factors'for DFS, DDFS, and OS in 144 Patie*zts With HRPBC Treated Accordi~g tothe Tandem 
HD C7' Protocol* 
Pt 
Variable DFS DDFS OS 
Age at diagnosis, y, <35/versus 35-45 versus >45 
Stage, II versus III 
Premenopausal versus postmenopausal 
No. of tumor-involved ALN, < I 0 versus I 0-19 versus > 19 
Nodal ratio, <0.8 versus >0.8 
Tumor  size, pTI  versus pT2 versus pT3 versus pT4 
Grading, G I versus G2 versus G3 
ER or PR positive versus ER and PR negative 
Cytokeratin-positive cells in BM, yes versus no~ 
HER2/neu, 3+ versus -<2+w 
BCT versus MRM 
Locoregional radiotherapy, yes versus no 
.161 .347 .023 
.379 .337 .040 
.887 .458 .795 
.236 .393 .834 
.019 .188 .326 
.294 .592 .634 
.801 .571 .096 
.108 .219 .007 
.751 .855 .870 
.093 .230 .017 
.538 .514 .408 
.063 .327 .437 
*DFS indicates disease-free survival; DDFS, distant disease-free survival; OS, overall survival; HRPBC, high-risk primary breast cancer; HDCT, 
high-dose chemotherapy; ALN, axillary lymph nodes; ER, estrogen receptor; PR, progesterone r ceptor; BM bone marrow aspirate; BCT, breast- 
conserving therapy (including adjuvant radiotherapy ofthe breast); MRM, modified radical mastectomy. 
?P value of log-rank tests. 
~Only patients in whom bone marrow was examined (n = 79). 
~Only patients with known ttER2/neu status (n = 121). 
greater than grade 2 was stomatitis, which developed in 35 % 
of patients, requiring total parenteral nutrition for a maxi- 
nmm of 13 days. Other grade 3 and 4 nonhematological toxi- 
cities, which occurred in 12 patients after the first and in 4 
patients after the second cycle of HDCT,  consisted of diar- 
rhea in 4 patients; vomiting, hemorrhagic olitis, fever, pneu- 
monia with dyspnea t rest, and neurologic disturbances, each 
in 2 patients; and elevation of liver enzymes and anaphylactic 
shock, each in 1 patient. The median number of days with 
fever (temperature _>38.5~ was 2.5 days (range, 0-14 days). 
As a result, the number of days of IV antibiotic therapy 
amounted to a median of 7 days (range, 0-23 days). Patients 
were hospitalized for a median of 20 days (range, 12-40 days). 
Univar ia te  and  Mu l t ivar ia te  Ana lyses  
For all 144 HRPBC patients treated according to the 
tandem high-dose protocol with a median fol low-up of 
46 months (range, 7-106 months), DFS, DDFS, and OS 
rates were 62%, 65%, and 84%, respectively (Figure 2). 
Relapses after HDCT occurred in 53 (37%) of 144 patients 
as of January 2001 and were observed locoregionally (ipsilat- 
eral breast, ipsilateral chest wall, above the ipsilateral clavi- 
cle, or in the ipsilateral ALN) as first relapse in 13 (25%) of 
53 patients. Distant metastases developed in 45 (85%) of 
53 patients (bone, 24 patients; liver or lung, 14 patients; cen- 
tral nervous system, 6 patients; soft tissue, 6 patients; pleura, 
2 patients; per i toneum, 1 patient; ovary, 1 patient). In 
13 patients, first relapse occurred in more than 1 site. 
In univariate analysis, only a nodal ratio of_>0.8 was 
associated with shorter DFS time (P -- .019). A trend for 
earlier relapse was seen in patients with overexpression of 
HER2/neu (P = .093) and no locoregional radiotherapy to 
the chest wall or draining lymph nodes (P = .064). None 
of the evaluated factors was associated with DDFS.  
Besides age at diagnosis (P = .023), stage (P = .040), and 
HER2/neu overexpression (P = .017), the strongest pre- 
dictor of inferior OS time was a negative hormone-receptor 
status (P = .007) (Table 3). 
Table 4. Results" of the Multivariate Analysis: Indepe~dent Prog,zostic l~)lctors for DFS and OS in 144 Patients" With [IRPBC Tveated According to the Tan- 
dem HDCT Protocol* 
DFS OS 
Variable RR (95% CI) Pt RR (95% CI) Pt 
Age at diagnosis, y, <35 versus 35-45 versus >45 
Stage, II versus III 
Nodal ratio, <0.8 versus _>0.8 
ER or PR positive versus ER and PR negative 
HER2/neu, 3+ versus _<2+ 5
0.70 (0.48- 1.02) .064 I. I I (0.33- 1.04) .070 
0.85 (0.47-1.56) .606 1.69 (0.66-4.34) .272 
2.09 (I .21-3.60) .008 1.41 (0.58-3.43) .449 
1.50 (0.84-2.70) 9 175 3.59 (I .45-8.86) .006 
1.47 (0.77-2.82) .247 1.49 (0.53-4.15) .446 
*DFS indicates disease-free survival; OS, overall survival; HRPBC, high-risk primary breast cancer; HDCT, high-dose chemotherapy; RR, risk 
ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone r ceptor. 
tP value of Cox regression analysis. 
:~Only patients with known HER2/neu status (n = 121). 
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Figure 3. Disease-free survival (DFS) rates following the initial 
surgery according to the nodal ratio (number of tumor-involved axil- 
la W lymph nodes/number of sampled axillary lymph nodes). 
In multivariate analysis, a nodal ratio of_>0.8 remained 
an independent predictor of shorter DFS time (relative risk 
[RR] = 2.09; 95% confidence interval [CI], 1.21-3.60; P = 
.008). So far, the 6nly independent predictor of a shorter OS 
time has been the absence of ER and PR (RR = 3.59; 95% 
CI, 1.45-8.86; P =.006) (Table 4). As a consequence, patients 
with a nodal ratio of_>0.8 were estimated to have DFS prob- 
abilities of 34% at 5 years compared to 60% for patients 
with a nodal ratio of <0.8 (Figure 3), according to Kaplan- 
Meier analysis. For patients with negative ER and PR, OS 
probability was significantly lower than in patients whose 
tumors expressed at least 1 receptor (61% and 83% at 
5 years, respectively) (Figure 4). 
100 
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~1 H I  I I I I  t I ]  t H I I I  
q I 
P = .006 ER and PR negative (n = 51) 
9 - i . . . .  r . . . .  i . . . . . . . .  | J . . . .  
20 40 60 80 100 120 
OS (months) Figure 4. Overall survival rates (OS) following the initial surgery 
according to the combined estrogen receptor (ER) and progesterone 
receptor (PR) status. 
assigned to a patient from the cancer egistry of the Univer- 
sity of Heidelberg Department of Gynecology and Obstet- 
rics who matched all 4 of the abovementioned criteria and 
was treated conventionally during the same period. Fifty- 
three HDCT patients could not be matched to a conven- 
tionally treated patient and therefore were excluded from 
the matched-pair analysis. 
In both treatment groups of this matched-pair analysis, 
the patients' characteristics were well balanced for the match- 
ing criteria and for other criteria not used for matching, such 
as grading and type of surgical procedure. Notably, more 
patients in the HDCT group than patients in the convention- 
ally treated group were younger than age 35 years at diagnosis, 
had 10 or more tumor-involved ALN, and received adjuvant 
radiotherapy to the chest wall or draining lymph nodes. 
With a median follow-up of 3 years, matched-pair analy- 
sis demonstrated a trend toward better DDFS rates after 
I t  I 
100 
80. 
60- 
. . (3  
. .Q  
s 40- 8. 
201 P = .( 
0 . . . .  
0 
.059 
20 
HDCT 
Matched-Pair  Analysis 
Using the risk factors defined by Nieto et al. [112,13] 
(nodal ratio, tumor size, combined hormone receptor status, 
and expression of HER2/neu) and confirmed by the results 
of our analysis, 91 of the 144 HDCT patients could each be 
9 - i . . . .  1 . . . .  i . . . .  = - 9 
40 60 80 100 
DDFS (months) 
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Figure 5. Distant disease-free survival (DDFS) rates (A) and overall 
survival (OS) rates (B) of 182 matched patients following the initial 
surgery according to the adjuvant chemotherapy. HDCT indicates 
high-dose chemotherapy; CCT, conventional chemotherapy. 
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Figure 6. Distant disease-free survival (DDFS) (A) and overall survival 
(OS) rates (B) of 104 matched patients following the initial surgery, 
who received anthracycline-containing conventional chemotherapy 
(A-CC~I) or high-dose chemotherapy (HDCT). 
HDCT than after conventional chemotherapy (P = .059). 
There was no difference in OS rates (P = .786) (Figure 5). 
Considering only the subgroup of 104 patients who received 
anthracycline-containing adjuvant chemotherapy, HDCT 
was not found to be significantly superior to conventional 
chemotherapy with respect to DDFS rates (P = .849) or OS 
rates (P = .620) (Figure 6). Along the same lines, considering 
only patients with or without overexpression f HER2/neu, 
matched-pair analysis revealed no significant difference in 
DDFS and OS rates between the high-dose and standard- 
dose groups (HER2/neu 3+, 44 patients: DDFS, P -- .108 
and OS, P = .204; HER2/neu 0-2+ or unknown, 138 
patients: DDFS, P = .174 and OS, P = .733). 
DISCUSSION 
Multiple single-ann studies suggest hat HDCT may 
improve the results of conventional chemotherapy in 
HRPBC [19-24]. Because conclusive mature data from large 
randomized studies are still pending, it would be worthwhile 
to better characterize the subgroups of HRPBC patients 
who may derive major benefit from HDCT, whereas other 
patients may require different approaches. 
In univariate analysis, probably due to the small number 
of patients (n = 22), we only found a trend for earlier elapse 
in patients with HER2/neu overexpression (P = .093). 
Regarding OS, however, HER2/neu overexpression proved 
to be a predictor for earlier death (P = .017). When we eval- 
uated the well-established prognostic factors used to distin- 
guish prognostic groups in the adjuvant setting [24] in 
combination with nodal ratio, HER2/neu, and presence of 
cytokeratin-positive bone marrow cells, the nodal ratio was 
revealed to be the only independent predictor for relapse 
(RR = 2.09; 95% CI, 1.21-3.60; P = .008]. So far, in multi- 
variate analysis, ER or PR positivity has been the only inde- 
pendent predictor for increased OS rates (RR = 3.59; 95% 
CI, 1.45-8.86; P = .006), in part reflecting the efficacy of the 
additional antihormonal treatment before and after relapse 
in patients with ER- or PR-positive tumors. We found no 
association between the detection of cytokeratin-positive 
cells in bone marrow aspirate and DFS or OS rates. 
Somlo et al. examined stage, tumor size, number of 
involved ALN, grade, hormone receptor status, and differ- 
ent types of adjuvant HDCT and radiotherapy as tumor- 
and treatment-specific prognostic indicators for RFS and 
OS rates in 114 HRPBC patients. With a median follow-up 
of 46 months, PR positivity was the only independent pre- 
dictor of increased survival rates in multivariate analysis 
[25]. Evaluating 23 variables in a more homogeneous group 
of 176 HRPBC patients with 4 or more tumor-involved 
ALN or inflammatory breast cancer treated with the same 
HDCT regimen, Nieto et al. determined that axillary nodal 
ratio (number of involved ALN/number of dissected ALN; 
<0.8 versus >0.8), ER/PR combined status (positive versus 
negative), and tumor size (<2 cm versus 2-5 cm versus >5 
cm) were the only independent predictors for relapse. In a 
further analysis, in which the prognostic value of HER2/neu 
status was evaluated in a subgroup of 146 patients, the inves- 
tigators found significantly lower RFS and OS rates in 
patients with HER2/neu overexpression. After adjustment 
for nodal ratio, ER/PR combined status, and tumor size, 
HER2/neu overexpression remained an independent ega- 
tive predictor for relapse and death [12,13]. 
In our analysis, detection of cytokeratin-positive bone 
marrow cells by immunocytochemical analysis was not asso- 
ciated with relapse or death. In contrast, Fields et al. 
reported that the incidence of occult bone metastases 
detected by polymerase chain reaction for K19 in 83 patients 
with high-risk stage II, III, or 1V breast cancer undergoing 
HDCT with autologous stem cell transplantation after con- 
ventional induction chemotherapy was associated with ear- 
lier relapse [26]. Along the same lines, Vredenburgh et al. 
found an association between tumor cell contamination 
in bone marrow detected with a panel of 4 anti-breast 
cancer monoclonal antibodies and DFS and OS rates in 
83 HRPBC patients with 10 or more tumorqnvolved ALN 
who received standard-dose induction chemotherapy fol- 
lowed by consolidation with stern cell-supported HDCT 
[27]. We analyzed bone marrow aspirated before chemo- 
therapy; Fields et al. and Vredenburgh et al. searched for 
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persistent umor cell contamination after induction 
chemotherapy, which might be associated with a worse 
prognosis [28]. 
Braun et al. found that the presence of occult cytoker- 
atin-positive metastatic ells detected by the monoclonal 
antibody A45-B/B3 in bone marrow aspirates obtained from 
552 patients with stage I to III breast cancer increased the 
risk of distant relapse and death [29]. However, no data are 
available on the subgroup of 85 patients who had 10 or 
more tumor-involved ALN, as did ahnost all patients in our 
analysis. The number of patients may be too small to detect 
any difference, or this subgroup may represent patients with 
near-site metastatic disease, in which the detection of cytok- 
eratin-positive bone marrow cells no longer distinguishes 
between high- and low-risk patients. Furthermore, we used 
a different panel of 4 monoclonal epithelial-specific antibod- 
ies, which might have a different sensitivity and specificity in 
tumor cell detection. 
Considering all 144 patients included in the present tan- 
dem HDCT study, we achieved DFS, DDFS, and OS rates of 
62%, 65%, and 84%, respectively, at a median follow-up 
period of 46 months. Following administration of a total of 
277 cycles of PBSC-supported HDCT (in 94% high-dose 
ifosfamide, epirubicin, and carboplatin), no treatment-related 
deaths occurred. The scheduled treatment had to be discon- 
tinued after the first of 2 cycles of HDCT in only 11 (8%) of 
144 patients because of refusal to proceed in 5 patients and 
toxicity in the other 6 patients. So far, we have not observed 
any serious chronic side effects or long-term sequelae. 
Although a large number of HDCT regimens with autol- 
ogous stem cell transplantation have been evaluated for treat- 
ment of breast cancer, they have never been directly com- 
pared in a randomized fashion. Comparison of our results 
with previously published ata from other single-arm studies 
with sufficient numbers of patients and follow-up and with 
tee dam from the Autologous Bone Marrow Transplantation 
Registry of North America (ABMTR) indicated that the effi- 
cacy of out" HDCT regimen is very similar to that of other 
regimens including sequential high-dose approaches. In 67 
HRPBC patients with 10 or more tumor-involved ALN who 
received a sequential HDCT regimen with a median follow- 
up period of 4 years, Gianni et al. reported a probability of 
RFS and OS of 57% and 70%, respectively [6]. The 100-day 
mortality rate was about 1% to 2%. Peters et al. reported 
event-free survival and OS rates of 62% and 69%, respec- 
tively, with a follow-up of 6.9 years in a similar risk group of 
85 breast cancer patients who received 4 cycles of cyclophos- 
phamide, doxorubicin, and 5-fluorouracil followed by 1 cycle 
of stem cell-supported HDCT [30]. The early mortality rate, 
however, was 12% [5]. In 1353 breast cancer patients with 
stage II and III disease (more than 70% had 10 or more 
tumor-involved ALN) who received stem cell-supported 
HDCT and whose data were reported to the ABMTR 
between 1989 and 1995, 3-year RFS and OS rates of 60% to 
65% and 70% to 74%, respectively, were achieved. Mortality 
dropped from 22% to 5% during this period [31]. 
To evaluate the relative value of our tandem HDCT 
regimen compared with conventional chemotherapy in 
HRPBC patients treated at our institution during the same 
period, we matched 91 patients assigned to the high-dose 
protocol to a comparable group of patients who received a
standard-dose chemotherapy using the prognostic factors 
determined by Nieto et al. and confirmed by the results of 
our univariate and multivariate analyses. Because of signifi- 
cant imbalances between the high-dose and the standard- 
dose chemotherapy treatment groups in the number of 
patients who received adjuvant locoregional radiotherapy to
the chest wall or draining lymph nodes, it did not seem 
worthwhile to compare isolated local recurrence rates. Con- 
sidering DDFS and OS rates with a median follow-up 
period of 3 years, matched-pair analysis demonstrated a 
trend toward higher DDFS rates after HDCT than after 
conventional chemotherapy (P = .059). Thus far, no differ- 
ence in OS rates has been found (P = .786). Furthermore, 
we found no difference in DDFS and OS rates between the 
high-dose and standard-dose chemotherapy in the subgroup 
of 104 patients who received a treatment regimen contain- 
ing anthracycline (DDFS, P = .686; OS, P = .666) and in the 
subgroups of patients with HER2/neu overexpression (n = 44; 
DDFS, P = .465; OS, P = .378) or without HER2/neu over- 
expression or with unknown HER2/neu status (n = 138; 
DDFS, P ~- .298; OS, P ; .887). Only 5 patients in the conven- 
tional therapy cohort were rescued with stem cell-supported 
HDCT. However, the limited follow-up period does not 
allow definite conclusions with respect to survival. 
Thus far, the results from randomized trials are prelim- 
inary and inconclusive. Hortobagyi et al. first presented 
negative results from a small prematurely closed random- 
ized study of 78 HRPBC patients. Besides the low statistical 
power, this study has some other weaknesses, including dif- 
ferent pretreatments, considerable cross-over between 
treatment arms, and inadequate low doses of cylophos- 
phamide in the high-dose regimen, so that no valid com- 
parison can be made between high-dose and standard-dose 
chemotherapy [8]. Similarly, the negative results of a small 
study of 81 patients published by Rodenhuis et al. in 
1998--with a power to detect an absolute difference of 
approximately 35% further impaired by a deviation of 
approximately 15% of patients from assigned treatment-- 
do little to help define the role of HDCT in HRPBC. Fur- 
thermore, the time delay of approximately 8 weeks due to 
surgery after 2 cycles of primary 5-fluorouracil, epirubicin, 
and cyclophosphamide (FEC) before the HDCT may have 
allowed regrowth of tumor cells, thereby compromising 
any potential benefit from HDCT [7]. Bergh et al. random- 
ized 525 patients to 3 cycles of FEC (total dose of epiru- 
bicin, only 180 mg/m 2) followed by 1 cycle of high-dose 
cyclophosphamide, thiotepa, and carboplatin versus 9 
courses of an escalated FEC regimen. The escalated oses 
in the "tailored-FEC" arm resulted in a 3-fold increase of 
5-fluorouracil, a 5.5-fold excess of epirubicin, and a 1.4- 
fold increase in cyclophosphamide, which may have 
caused the early occurrence of 9 cases of acute myeloid 
leukemias/myelodysplastic syndromes in this arm. There- 
fore, this group actually compared an underdosed high- 
dose arm with a very aggressive intermediate-dose arm, 
which does not allow comparison of high-dose with stan- 
dard-dose chemotherapy [10]. Peters et al. randomized 783 
patients after 4 cycles of cyclophosphamide, doxorubicin, 
and 5-fluorouracil (CAF) to 1 cycle of consolidation with 
either high-dose or intermediate-dose cyclophosphamide, 
cisplatin, and BCNU. With a median follow-up period of 
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42 months,  event-free survival was not  signif icantly differ- 
ent between the 2 treatment arms. Consider ing the first 3 
years, however, there was a 34% reduct ion in relapse fre- 
quency in the h igh-dose arm compared with the contro l  
arm. At pre l iminary analysis, this benefit  was outweighed 
by an unacceptably high mortal i ty  rate of 7%, with a 3% 
100-day morta l i ty  rate [9]. On behalf  of the Nether lands  
Work ing  Par ty  on Auto logous  Transp lantat ion  in Sol id  
Tmnors  at the 36th Annual Meet ing of the American Soci- 
ety of Cl inical Oncolog y (May 20-23, 2000, New Orleans, 
LA), Rodenhuis  et al. reported for the first t ime a signifi- 
cant superior i ty of HDCT to standard-dose chemotherapy 
with respect o progression-free survival rates (P -- .009) and 
OS rates (P = .039) in a planned subgroup analysis of the 
first 284 patients after a median fol low-up period of 3 years 
[11]. Some other randomized trials have already f inished 
accrual, but  their results are still pending. 
In summary, the data are inconclusive so far regarding 
the superiority, or lack thereof, of HDCT over conventional 
chemotherapy, qb define the role of HDCT in HRPBC,  we 
wil l  have to wait  another  2 years for the data to mature.  
However,  even if this positive trend continues and reaches 
statist ical  signif icance, HDCT might  save only a certain 
subgroup of HRPBC patients from relapse and ul t imately 
death from the disease. I f  we do not  have better predictive 
factors, we need better prognost ic features uch as the nodal 
ratio or the expression of HER2/neu  to help better define 
the group of patients who require aggressive adjuvant reat- 
ment. HDCT should be considered as a part of this adjuvant 
t reatment in conjunction with novel therapeutic approaches, 
including signal transduction inhibitors, vaccines, and bio-  
logical response modifiers. 
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